MAM
Fabindia appoints Aditya Ghosh to board of directors
NEW DELHI: Fabindia Group has appointed Aditya Ghosh as a member of the company’s board of directors. Ghosh will be guiding the management teams with strategy and new initiatives.
Ghosh said, "I am truly excited to come on board and get associated with a brand that I have been a loyal customer and fan of, for decades! I am looking forward to engaging with a sense of purpose where we continue to build on the tremendous trust that the Fabindia family of brands enjoy and create a socially conscious business that makes a deep positive impact towards a healthier and more equal planet."
Fabindia believes that the post-Covid2019 period will bring about transformational change in consumer behaviour and brands with purpose, sustainability initiatives and earth-friendly commerce will become increasingly important.
Ghosh is a seasoned professional with over 22 years of experience. Ghosh has had multiple roles as the CEO and Board member of large consumer-facing businesses with complex operations including IndiGo, India's largest and most profitable airline and also OYO Hotels & Homes. He also sits on the board of directors of Nani Palkhivala Arbitration Centre. He is one of the founders of The Ashoka University and Member Circle of Sponsors where he is actively involved in leading the service excellence aspect.
Before his business role, he practised law at the prestigious corporate law firm, J Sagar Associates and then as the general counsel at InterGlobe Enterprises. Ghosh has a keen interest in creating social impact in diversity & inclusion, education, women-led entrepreneurship and leadership development.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
